Acorda Therapeutics, Inc. (ACOR) recently announced that an additional method of use patent (US patent application no. 8,440,703) related to Ampyra twice-daily dosing of less than 15 mg has been issued by the US Patent and Trademark Office (:USPTO).
We note that two method of use patents for Ampyra have already been issued by the USPTO in 2011 and 2013, which are valid till 2027 and 2026, respectively. The ‘703 method of use patent will protect Ampyra till 2025.
We remind investors that the US Food and Drug Administration (:FDA) approved Ampyra in Jan 2010 for the improvement of walking in multiple sclerosis patients. Ampyra is available outside the US under the trade name Fampyra. Acorda has a license and collaboration agreement with Biogen Idec (BIIB) for the development and commercialization of Fampyra outside the US.
Ampyra is being studied for other indications as well including cerebral palsy (encouraging efficacy data reported in Apr 2013 from a phase II proof-of-concept study) and post-stroke deficits (positive top-line data from a phase II proof-of-concept study reported in Apr 2013). The company plans to undertake further development of Ampyra for the post-stroke deficit indication.
We believe that approval for additional indications will boost Ampyra sales. However, we remain worried about the company’s over dependence on Ampyra for growth
Acorda carries a Zacks Rank #3 (Hold). Currently, companies like Santarus, Inc. (SNTS) and Jazz Pharmaceuticals (JAZZ) look attractive with both being Zacks Rank #1 (Strong Buy) stocks.
More From Zacks.com